New drug duo tested to fight tough cancers with genetic flaws
NCT ID NCT05694715
Summary
This early-stage study aims to find a safe and effective dose for combining two cancer drugs, niraparib and irinotecan. It is for adults with advanced solid tumors (like certain breast, ovarian, or pancreatic cancers) that have spread and have specific mutations in genes like BRCA, ATM, or PALB2. The main goal is to see how well patients tolerate the combination and to find the best dose for future testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.